| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b/2a data readout example | Phase 1b/2a | — | Subscribe to access the data. | Gene Therapies | Musculoskeletal System | ||
Phase 1b/2a data readout example | Phase 1b/2a | — | Subscribe to access the data. | Gene Therapies | Musculoskeletal System | ||
Phase 1b/2a data readout example | Phase 1b/2a | — | Subscribe to access the data. | Gene Therapies | Musculoskeletal System |
Recent Updates
Recently added Catalysts
Benitec Biopharma Inc.$11.71
-0.15 (-1.26%)
D 34Pipeline Score Overvalued Biotech · Clinical
Market Cap
385.80 M
EPS
-0.93
P/E Ratio
-
Value Trade
924.11 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
6.30 M
Total Assets
187.00 M
Total Liabilities
3.67 M
Equity
183.33 M
D/E Ratio
12,345
-1.23 %
Week
-15.5 %
1 Month
4.56 %
3 Month
-14.08 %
6 Month
-84.99 %
5 Year
-99.53 %
All Time
Cash Data
Cash Position
184.76 M
Monthly Burn
4.53 M
Runway
38.3 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
107.53 K
52 Week Range
9.85 - 17.15
% held by Insiders
2.55 %
% held by Institutions
96.65 %
Enterprise Value
201.80 M
Total Shares
34.35 M
Short %
10.76 %
Float Shares
21.09 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Benitec Biopharma Inc.
154Total events
1Upcoming
26Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 1
TBD
T2Oral Presentation
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutBB-301Clinical Data
Subscribe to view catalyst details
TBD
◆Oral PresentationBB-301Presentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-03-09 | BB-301 (low dose, Cohort 1) | Phase 1b/2a interim results | Phase 1b/2a | — | – | – | – |
2026-03-09 | BB-301 (low dose, Cohort 1) | Phase 1b/2a interim results | Phase 1b/2a | — | – | – | – |
2026-03-09 | BB-301 (low dose, Cohort 1) | Phase 1b/2a interim results | Phase 1b/2a | — | – | – | – |
Drug Pipeline Intelligence
D34
Pipeline Score $150M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.4x
rNPV / MCap Top 48%
Micro Cap (rank 476 of 913)
Percentile RankBenitec Biopharma Inc. faces pipeline headwinds (34/100), with $376M risk-adjusted pipeline value, led by BB-401 in Head and Neck Squamous Cell Carcinoma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BB-401 Small molecule | Head and Neck Squamous Cell Carcinoma | Phase 2 | NCT03433027 | 10% | $376M | COMPLETED | 16 | - | - | Apr 6, 2020 | - | Apr 15, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BB-301 Fast TrackOrphan | Oculopharyngeal Muscular Dystrophy | Phase 1b/2a | 2026-05-14 | durable responses to low dose BB-301 at 12-months and 24-months post-treatment; further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point; all six Cohort 1 patients have safely completed the 12-month post-BB-301-treatment follow-up period and continue to experience robust responses to the low dose of BB-301; the first two Cohort 2 patients have been safely treated with the high dose of BB-301 Read More | Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update Read More | |
BB-301 Fast TrackOrphan | Oculopharyngeal Muscular Dystrophy | Phase 1b/2a | 2026-05-14 | durable responses to low dose BB-301 at 12-months and 24-months post-treatment; further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point; all six Cohort 1 patients have safely completed the 12-month post-BB-301-treatment follow-up period and continue to experience robust responses to the low dose of BB-301; the first two Cohort 2 patients have been safely treated with the high dose of BB-301 Read More | Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update Read More | |
BB-301 Fast TrackOrphan | Oculopharyngeal Muscular Dystrophy | Phase 1b/2a | 2026-05-14 | durable responses to low dose BB-301 at 12-months and 24-months post-treatment; further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point; all six Cohort 1 patients have safely completed the 12-month post-BB-301-treatment follow-up period and continue to experience robust responses to the low dose of BB-301; the first two Cohort 2 patients have been safely treated with the high dose of BB-301 Read More | Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BNTC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BNTC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BNTCBenitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma reported its third-quarter 2026 financial results alongside key updates on its BB-301 clinical program for Oculopharyngeal Muscular Dystrophy. The results showcased promising clinical data, demonstrating durable responses in patients treated with BB-301. The Company announced plans to engage the FDA on the pivotal study design mid-year and has successfully treated patients in ongoing clinical trials. With a robust cash position, Benitec is well-prepared to advance BB-301, positioning itself closer to potential approval.
Read more →BNTCBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Benitec Biopharma announced the acceptance of interim results from its BB-301 Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy (OPMD). The results, which show durable improvements in patients, will be presented at the 2026 ASGCT Annual Meeting. BB-301 is a unique gene therapy targeting dysphagia in OPMD patients, with no approved therapies currently available.
Read more →BNTCBenitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
Benitec Biopharma Inc. is set to host an Industry Forum Breakfast at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026. The event will showcase the clinical results of BB-301, a treatment in development for Oculopharyngeal Muscular Dystrophy (OPMD), which currently has no approved therapies. CEO Jerel A. Banks will present findings showing substantial improvements in dysphagic symptoms for patients treated with BB-301, emphasizing its potential to transform OPMD treatment. The conference is aimed at industry stakeholders and will also be accessible via live stream.
Read more →BNTC▲ +10.7%on this newsshared move
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma announced positive interim results from its Phase 1b/2a study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). Patients receiving both low and high doses of BB-301 showed significant improvements in swallowing function, with durable effects lasting up to two years. The high dose demonstrated a robust response, indicating potential for disease-modifying outcomes.
Read more →BNTCBenitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma has announced the acceptance of a late-breaking abstract for its BB-301 Phase 1b/2a clinical study at the Muscular Dystrophy Association Clinical & Scientific Conference. The study focuses on treating Oculopharyngeal Muscular Dystrophy (OPMD) patients with moderate dysphagia. Interim results for both Cohort 1 and Cohort 2 will be presented, highlighting the potential of BB-301 as a treatment option.
Read more →BNTCBenitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma reported positive results from its BB-301 Phase 1b/2a study, with all four patients in Cohort 1 showing durable responses after 12 months. Patient 1 continued to experience significant improvements at the 24-month follow-up. The company plans to engage with the FDA regarding the pivotal study design in mid-2026 and has received Fast Track Designation for BB-301.
Read more →BNTCBenitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
Benitec Biopharma has announced promising long-term results from its BB-301 Phase 1b/2a clinical trial for treating dysphagia associated with oculopharyngeal muscular dystrophy. Notably, Patient 1 showed marked disease-modifying improvements over a 24-month follow-up period, reporting significant reductions in post-swallow residue and symptom burden. All four patients in the initial cohort completed the 12-month follow-up and showed durable responses to the treatment, with further evaluations expected moving forward. The company plans to engage with the FDA regarding the next steps in development.
Read more →BNTCBenitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim
Benitec Biopharma announced its first quarter 2026 financial results, highlighting significant achievements including the FDA granting Fast Track Designation to its lead product BB-301. The interim results from the Phase 1b/2a trial indicated a 100% responder rate among patients in Cohort 1. Additionally, the company raised $100 million in a public offering to support further development of its Oculopharyngeal Muscular Dystrophy program. However, the financial report showed an increased comprehensive loss and net loss for the period compared to the previous year.
Read more →BNTC▼ -24%on this news
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
Benitec Biopharma Inc. has announced the pricing of a $100 million common stock offering, which includes an underwritten public offering of 5,930,000 shares and a direct offering of 1,481,481 shares. The proceeds will be used to support product candidate programs and general corporate purposes. The offerings are set to close on November 7, 2025.
Read more →BNTC▼ -24%on this newsshared move
Benitec Biopharma Inc. Announces Proposed Public Offering
Benitec Biopharma Inc. has announced a proposed public offering of its common stock, alongside a registered direct offering with Suvretta Capital. The offerings are set to close on November 7, 2025, pending customary conditions. The company aims to raise funds to support its gene therapy initiatives, although market conditions may affect the final terms.
Read more →BNTCBenitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Benitec Biopharma announced positive interim results from its BB-301 Phase 1b/2a clinical trial, showing a 100% response rate among patients with Oculopharyngeal Muscular Dystrophy (OPMD). The FDA has granted Fast Track designation for BB-301, highlighting the urgent need for effective treatments for dysphagia associated with OPMD. The trial results indicate significant improvements in multiple clinical measures.
Read more →BNTCBenitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
Benitec Biopharma has appointed Dr. Sharon Mates to its Board of Directors, effective November 2, 2025. Dr. Mates, who has a strong background in biotechnology, is expected to contribute significantly to the company's BB-301 program aimed at treating Oculopharyngeal Muscular Dystrophy (OPMD). Her experience in advancing therapies from discovery to commercialization will be valuable as Benitec seeks regulatory approval for its innovative treatments.
Read more →BNTCBenitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Benitec Biopharma announced an upcoming update on its Phase 1b/2a clinical study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). The update will cover six patients from the initial cohort. The webcast is scheduled for November 3, 2025, at 8:00 am EST, reflecting the company's commitment to transparency in its clinical trials.
Read more →BNTCBenitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
Benitec Biopharma reported its financial results for the year ending June 30, 2025, highlighting an increase in operational losses and expenses. The company anticipates interim results for Cohort 1 of its BB-301 Phase 1b/2a study in Q4 2025 and has received approval to begin enrollment for Cohort 2. The financial report indicates a substantial cash reserve of $97.7 million.
Read more →BNTC▲ +9.7%on this news
Benitec Biopharma Provides Operational Updates
Benitec Biopharma announced that the independent Data Safety Monitoring Board has recommended the continuation of subject enrollment for its Phase 1b/2a clinical study of BB-301. The sixth and final subject of Cohort 1 was treated safely, and enrollment for Cohort 2 is expected to begin in Q4 2025. The company is optimistic about the safety profile of BB-301, which utilizes a local delivery method.
Read more →BNTC▲ +9.7%on this newsshared move
Benitec Biopharma Provides Operational Updates -In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent
Benitec Biopharma has provided updates on its Phase 1b/2a clinical treatment study of BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD). The independent Data Safety Monitoring Board completed a review and recommended that subject enrollment continues, with the sixth and final subject of Cohort 1 having been safely treated. Enrollment for Cohort 2 is anticipated to commence in the fourth quarter of 2025.
Read more →BNTCBenitec Biopharma Releases Third Quarter 2025 Financial Results
Benitec Biopharma Inc. announced its financial results for the third fiscal quarter of 2025, which ended on March 31, 2025. The company reported a significant increase in expenses, totaling $10.2 million, and a net loss of $9.4 million, up from $4.3 million in the same period the previous year. Despite these financial challenges, Benitec is focused on the clinical development of BB-301 for treating dysphagia in OPMD patients and has successfully treated all subjects in the first cohort. The company plans to enroll more subjects at a higher dose later this year and anticipates further clinical updates in the fourth quarter.
Read more →BNTCBenitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
Benitec Biopharma Inc. announced a $30 million common stock offering, consisting of both an underwritten and a registered direct offering. The company plans to use the net proceeds to support its developmental programs, working capital, and general corporate purposes. The offerings are expected to close on March 26, 2025, with Suvretta Capital participating as a long-term investor. The SEC has approved a registration statement for these securities, following which a prospectus supplement will be filed.
Read more →BNTCBenitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma reported positive interim results from its Phase 1b/2a study of BB-301 in treating Oculopharyngeal Muscular Dystrophy (OPMD). Three subjects showed significant improvements in swallowing function, with two achieving clinically normal profiles. These results will be presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference.
Read more →BNTCBenitec Biopharma to Participate in Upcoming Conferences in March
Benitec Biopharma Inc. has announced its participation in several upcoming healthcare conferences in March 2025, including the TD Cowen 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. The presentations will focus on the company's novel gene therapy platform, 'Silence and Replace', which addresses genetic conditions such as Oculopharyngeal Muscular Dystrophy (OPMD). These events will provide a platform for the management team to engage with investors and share advancements in their clinical-stage developments.
Read more →BNTC▲ +16%on this news
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
Benitec Biopharma Inc. announced that a late-breaking oral abstract for its BB-301 Phase 1b/2a clinical study has been accepted for presentation at the Muscular Dystrophy Association Conference. The presentation will discuss interim data showing improvements in swallowing function for subjects with Oculopharyngeal Muscular Dystrophy (OPMD). The study aims to provide a safe and efficacious treatment for dysphagia related to OPMD. The company is optimistic about sharing updated findings with the community on March 19, 2025.
Read more →BNTC▲ +16%on this news
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study upda
Benitec Biopharma has reported its second quarter 2025 financial results, highlighting the ongoing success of its BB-301 Phase 1b/2a clinical treatment study for Oculopharyngeal Muscular Dystrophy (OPMD). The company announced that five subjects have been safely treated with BB-301, showing improvements in swallowing function without severe adverse events. Financially, the company incurred a net loss attributable to shareholders of $7.4 million for the quarter, reflecting increased operational expenses. An interim update on the clinical study is scheduled to be presented at the upcoming Muscular Dystrophy Association Clinical & Scientific Conference in March 2025.
Read more →BNTCBenitec Biopharma to Participate in Upcoming Conferences in January and February
Benitec Biopharma Inc., a clinical-stage biotechnology company, has announced its participation in several upcoming conferences in January and February 2025. These conferences include the Muscular Dystrophy Association Gene Therapy Summit in Tucson, Guggenheim SMID Cap Biotech Conference in New York, and the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which will be held virtually. The company aims to showcase its innovative 'Silence and Replace' DNA-directed RNA interference platform that is being developed for various genetic disorders.
Read more →BNTCBenitec Biopharma to Participate in Upcoming Investor Conferences in December
Benitec Biopharma Inc. has announced its participation in two upcoming investor conferences in December 2024. The conferences include the Piper Sandler Annual Healthcare Conference and the Oppenheimer Movers in Rare Disease Summit, where the company's management will engage in discussions and meetings. This participation underscores Benitec's commitment to advancing its innovative genetic therapy pipeline and enhancing investor relations.
Read more →BNTCBenitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update -Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the
Benitec Biopharma has reported its first quarter financial results for fiscal year 2025 alongside an operational update. The company shared positive interim data from its ongoing Phase 1b/2a clinical study of BB-301, showing clinically meaningful improvements in dysphagic symptoms for treated subjects. With a net loss of $5 million in the reported quarter, Benitec remains financially equipped to advance its research, including plans for further subject enrollment at higher doses of BB-301 in the upcoming year.
Read more →BNTCBenitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
Benitec Biopharma Inc. has announced that CEO Jerel A. Banks will participate in the Guggenheim Securities Healthcare Conference from November 11-13, 2024, in Boston. The event will include a fireside chat as well as one-on-one meetings with potential investors. Benitec focuses on developing novel genetic medicines utilizing its proprietary 'Silence and Replace' DNA-directed RNA interference platform, aimed at treating chronic and life-threatening conditions. Attending this conference will allow for increased visibility and interaction with stakeholders in the healthcare sector.
Read more →BNTC▼ -6.4%on this news
Benitec Biopharma Announces Updated Investor Webcast Information
Benitec Biopharma announced revised details for an investor webcast scheduled for October 14th, 2024, aimed at discussing interim data from the BB-301 Phase 1b clinical study. The webcast will include management presentations and expert insights from Dr. Emily Plowman. BB-301 is being developed as a potential treatment for Oculopharyngeal Muscular Dystrophy (OPMD), a condition currently lacking effective therapies. The company emphasizes the innovative approach of its 'Silence and Replace' platform in addressing this unmet medical need.
Read more →BNTC▼ -6.4%on this newsshared move
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29 th Annual Congress of the World Muscle Society -Subject 1 and Subject 2 experienced durable, cli
Benitec Biopharma announced positive interim data from two subjects treated with low-dose BB-301 in a Phase 1b/2a study targeting Oculopharyngeal Muscular Dystrophy (OPMD). Both subjects demonstrated meaningful improvements in swallowing abilities at 9 months and 6 months post-treatment. Notably, one subject achieved a Sydney Swallow Questionnaire score indicative of clinically normal swallowing. The company plans to discuss interim results in a conference call scheduled for October 14, 2024.
Read more →BNTCBenitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update -Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed w
Benitec Biopharma has released its financial results for the full year 2024, highlighting positive interim clinical trial data for the BB-301 treatment in treating Oculopharyngeal Muscular Dystrophy (OPMD). The company successfully dosed a second subject and anticipates a third by the end of 2024. Despite delivering promising clinical updates, Benitec reported zero revenues for the year, reflecting a significant drop from the previous year's figures. The company has extended its cash runway through 2025 following a successful oversubscribed financing round of $40 million.
Read more →BNTCBenitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
Benitec Biopharma announced that an abstract on BB-301 has been accepted for oral presentation at the 29th Annual Congress of the World Muscle Society. The presentation will provide interim clinical data from a Phase 1b/2a study focusing on the safety and efficacy of BB-301 for treating Oculopharyngeal Muscular Dystrophy (OPMD), a rare disease with currently no effective therapies. The presentation is scheduled for October 12, 2024, and illustrates the company's commitment to advancing novel genetic medicines. Details on the oral presentation will be shared in a subsequent press release.
Read more →BNTCBenitec Biopharma CEO to Participate in OPMD Awareness Day Webinar
Benitec Biopharma Inc. CEO Jerel A. Banks will participate in the OPMD Awareness Day Webinar on September 23, 2024, which aims to raise awareness about Oculopharyngeal Muscular Dystrophy (OPMD). During the event, Banks will discuss the BB-301 Phase 1b/2a clinical development program, which involves a novel gene therapy approach targeting the underlying causes of OPMD. The webinar is intended to provide patients and their support networks with valuable clinical insights and resources related to the condition. OPMD is a rare, progressive muscle-wasting disease for which effective drug therapies are currently lacking.
Read more →BNTC▲ +7.7%on this news
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with L
Benitec Biopharma has reported positive interim results for BB-301 in a Phase 1b/2a study conducted on the first subject with Oculopharyngeal Muscular Dystrophy (OPMD). At the 180-day post-dose assessment, significant improvements were observed in both the radiographic assessments of swallowing efficiency and the subject-reported outcome measures. The data showed substantial reductions in Total Pharyngeal Residue and dysphagic symptoms, suggesting enhanced swallowing ability. The company plans to share further results in upcoming conferences and webcasts.
Read more →BNTCBenitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
Benitec Biopharma Inc. has appointed Kishen Mehta to its Board of Directors, effective June 26, 2024. Mehta brings over 15 years of experience in the financial industry and is anticipated to play a significant role in the company’s growth and the development of its gene therapy candidate BB-301 for Oculopharyngeal Muscular Dystrophy. This appointment follows a recent $40 million PIPE financing led by Suvretta Capital, which may provide additional resources for the company’s strategic plans. Benitec's proprietary technology aims to develop innovative treatments by silencing disease-causing genes while delivering functional replacements.
Read more →BNTC▼ -12.2%on this news
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update -Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in t
Benitec Biopharma reported its financial results for Q3 2024, highlighting positive interim clinical trial data from its BB-301 treatment for Oculopharyngeal Muscular Dystrophy (OPMD). The first subject dosed in the Phase 1b/2a trial exhibited meaningful improvements in clinical endpoints. Additionally, the company secured $40 million in funding which expands its operational runway into 2025. However, the financial report indicated a continued net loss and no revenue for the quarter, presenting challenges ahead.
Read more →BNTC▼ -6.5%on this news
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
Benitec Biopharma Inc. will participate in the Citizens JMP Life Science Conference in New York on May 13-14, 2024. The company's management, including CEO Jerel Banks, will present the innovative gene therapy technologies based on their proprietary 'Silence and Replace' platform. This presentation will be accessible via a live webcast, allowing broader engagement from interested stakeholders.
Read more →BNTC▲ +42.1%on this news
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study -First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal
Benitec Biopharma has announced positive interim results from its Phase 1b/2a clinical trial of BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD). The first subject treated showed significant improvements in swallowing function, measured by both objective and subjective assessments. These results are particularly noteworthy as no previous studies have systematically demonstrated clinical improvements in OPMD patients. The company continues to monitor safety, reporting no serious adverse events among trial participants thus far.
Read more →BNTC▲ +42.1%on this news
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
Benitec Biopharma announced an oversubscribed $40 million private placement financing through the sale of shares and pre-funded warrants. This financing was led by Suvretta Capital Management and included contributions from various institutional investors. The funds are intended to support the clinical development and commercialization of the company's gene therapy product, BB-301. The completion of this financing is expected by April 22, 2024, subject to customary conditions.
Read more →BNTCBenitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
Benitec Biopharma Inc. plans to host a virtual R&D Day on April 18, 2024, focusing on the clinical development of its gene therapy BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). The event will feature expert insights on OPMD’s clinical symptoms, natural history, and treatment landscape. Attendees can expect discussions on the clinical trial methods and endpoints related to BB-301. The event aims to enhance understanding of the ongoing efforts to combat this rare genetic disorder.
Read more →BNTCBenitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update -First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monit
Benitec Biopharma has announced its second quarter 2024 financial results, highlighting that the first subject was dosed with their gene therapy candidate, BB-301, in a Phase 1b/2a clinical study. The Data Safety Monitoring Board has completed its review and recommended to continue subject enrollment without modifications. Despite these advancements, the company reported a significant loss from operations and total revenues of $0 for the quarter. The firm aims to improve clinical outcomes for patients with Oculopharyngeal Muscular Dystrophy through its innovative treatments.
Read more →BNTCBenitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy Announcement marks the initiation of the first clini
Benitec Biopharma Inc. has dosed the first subject in its Phase 1b/2a clinical trial for BB-301, a gene therapy targeting Oculopharyngeal Muscular Dystrophy (OPMD). This event marks a crucial step in the evaluation of the drug, which aims to improve swallowing function in affected patients. The trial will assess safety and efficacy over a 52-week follow-up period, with interim evaluations every 90 days. BB-301 utilizes a novel Silence and Replace approach to manage the disorder by providing a functional replacement protein.
Read more →BNTCBenitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
Benitec Biopharma Inc. announced that its Executive Chairman and CEO, Jerel A. Banks, will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference on November 30, 2023. This engagement represents an opportunity for the company to highlight its proprietary ddRNAi platform and advancements in genetic therapies. The event aims to connect the company with potential investors and stakeholders interested in its innovative approaches to treating chronic diseases.
Read more →BNTCBenitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update 19 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for
Benitec Biopharma reported its financial results for the first fiscal quarter of 2024, highlighting the enrollment of 19 subjects in the OPMD Natural History Study. The company has received FDA clearance for the BB-301 IND application and is preparing to initiate dosing in early 2024. Although the company reported a net loss of $6 million and rising operating expenses, there is strong community interest and optimism surrounding the clinical execution of their therapies. The company continues to advance its gene therapy-focused pipeline, particularly targeting Oculopharyngeal Muscular Dystrophy.
Read more →BNTCBenitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscula
Benitec Biopharma (BNTC) announced its financial results for FY 2023, revealing a net loss of $19.6 million. The company received FDA clearance for its BB-301 investigational new drug application, aimed at treating dysphagia associated with Oculopharyngeal Muscular Dystrophy (OPMD). Additionally, Benitec successfully closed a public offering that raised $30.9 million, which is expected to support its ongoing clinical programs. Enrollment in the OPMD Natural History Study has exceeded expectations, further positioning the company for the upcoming Phase 1b/2a clinical treatment study.
Read more →BNTCBenitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
Benitec Biopharma Inc. successfully completed a $30 million underwritten public offering, selling 15,544,041 shares along with accompanying warrants. The offering aimed to finance the clinical development of BB-301, alongside other existing product candidates and general corporate purposes. Notably, well-known institutional investors participated in the offering, reflecting confidence in the company's strategic direction.
Read more →BNTCBenitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
Benitec Biopharma Inc. has priced its public offering at $30 million, involving 15,544,041 shares and accompanying warrants. The offering is anticipated to close on August 11, 2023, pending customary conditions. Proceeds will be directed towards advancing the clinical development of BB-301 and other strategic growth opportunities in the company's pipeline. Institutional investors such as Adage Capital Partners and Janus Henderson have shown interest in this offering.
Read more →BNTCBenitec Biopharma Announces 1-for-17 Reverse Stock Split Effective
Benitec Biopharma announced a 1-for-17 reverse stock split effective July 26, 2023, to comply with Nasdaq's $1.00 minimum bid price requirement. This decision was approved by the Board following stockholder consent at the annual meeting in December 2022. The split will take place automatically, with no action needed from stockholders for the adjustment. Despite this change, there is uncertainty regarding the company’s future compliance with Nasdaq listing standards.
Read more →BNTC▲ +80.9%on this news
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy Dosing of the first subject with BB-301 is expected in the second half of 2023, following the rollove
Benitec Biopharma has announced that the FDA has cleared its Investigational New Drug application for BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy. This marks a pivotal milestone as there are currently no approved treatments for this life-threatening condition. The first dosing of subjects in the clinical trial is anticipated in the latter half of 2023, with subjects from an ongoing Natural History study being eligible to enroll. BB-301 aims to provide a novel approach by silencing the faulty gene responsible for the disorder while replacing it with a functional version, potentially alleviating severe symptoms associated with OPMD.
Read more →BNTCBenitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update 9 subjects enrolled into the OPMD clinical development program
Benitec Biopharma has reported its financial results for the third quarter of 2023, highlighting the enrollment of 9 subjects into its OPMD clinical development program. The company anticipates disclosing interim safety and efficacy data for its BB-301 treatment in the second half of 2023. Despite a year-over-year increase in operating expenses and a net loss of $4.4 million, enrollment is progressing at a rapid pace. Additionally, Benitec is focused on expanding its clinical study sites in Canada and France, contingent upon regulatory approvals.
Read more →BNTCBenitec Biopharma to Present at the OPMD International Conference
Benitec Biopharma Inc. is set to present its BB-301 Clinical Development Program at the Oculopharyngeal Muscular Dystrophy International Conference on May 16, 2023. CEO Jerel A. Banks expressed optimism about rapid enrollment of subjects into the Natural History Study, which is critical for advancing their therapeutic development. The company aims to begin administering its treatment to OPMD subjects in the latter half of 2023 while also disclosing interim efficacy and safety data for enrolled participants.
Read more →BNTCBenitec Biopharma to Present at the JMP Securities Life Sciences Conference
Benitec Biopharma Inc. has announced that its Executive Chairman and CEO, Jerel A. Banks, will present at the JMP Securities Life Sciences Conference on May 16, 2023. This event highlights the company's focus on developing novel genetic medicines through its proprietary ddRNAi platform, which aims at treating chronic and life-threatening conditions like Oculopharyngeal Muscular Dystrophy. Investors can view the presentation live via webcast on the company's website, with an archived version available for 90 days afterward.
Read more →BNTCBenitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update First subject enrolled into the OPMD clinical development program
Benitec Biopharma Inc. reported its financial results for the second fiscal quarter of 2023, noting revenues of $14,000 and operating expenses totaling $5.6 million. The company successfully enrolled the first patient in the OPMD clinical development program, marking a significant milestone. Despite an increase in net losses, which rose to $5.4 million, Benitec continues to focus on advancing its gene therapy projects. The financial outlook highlights a cash balance of $10.5 million as of December 31, 2022.
Read more →BNTC▲ +9.1%on this news
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program
Benitec Biopharma has successfully enrolled its first patient for the OPMD natural history phase of its BB-301 clinical development program. This phase involves a six-month observation period assessing the patient's condition before administering the treatment for dysphagia related to oculopharyngeal muscular dystrophy. The company has reported high interest in participation from potential subjects, which supports its goal to initiate the treatment study within the year. Benitec is also working towards expanding its clinical trial sites internationally.
Read more →BNTC▲ +5.8%on this news· ran to +16% by day 3
Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update
Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update HAYWARD, Calif., November 10, 2022 Benitec Biopharma Inc. (NASDAQ: BNTC) ( Benitec or the Company ), a development-stage, gene therapy-focused, biotechnology company developing nove
Read more →BNTC▼ -15.4%on this news· ran to -28% by day 3
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddR
Read more →BNTC▼ -6.6%on this news· ran to -37% by day 3
Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering
Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering HAYWARD, Calif., September 12, 2022 Benitec Biopharma Inc. (Nasdaq: BNTC) ( Benitec or the Company ), a development-stage, gene therapy-focused, biotechnology company developing novel genetic m
Read more →BNTCBenitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update
Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update HAYWARD, Calif., September 2, 2022 Benitec Biopharma Inc. (NASDAQ: BNTC) ( Benitec or the Company ), a development-stage, gene therapy-focused, biotechnology company developing novel gen
Read more →BNTC▼ -8.8%on this news
Benitec Biopharma Releases Q3 2022 Financial Results
Benitec Biopharma Releases Q3 2022 Financial Results HAYWARD, Calif., May 16, 2022 Benitec Biopharma Inc. (NASDAQ: BNTC) ( Benitec or the Company ), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-
Read more →BNTCBenitec Biopharma Discloses Q2 2022 Financial Results
Benitec Biopharma Discloses Q2 2022 Financial Results HAYWARD, Calif., February 14, 2022 Benitec Biopharma Inc. (NASDAQ: BNTC) ( Benitec or the Company ), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietar
Read more →BNTCBenitec Biopharma Discloses Q1 2022 Financial Results
Benitec Biopharma Discloses Q1 2022 Financial Results HAYWARD, Calif., November 15, 2021 Benitec Biopharma Inc. (NASDAQ: BNTC) ( Benitec or the Company ), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietar
Read more →BNTC▼ -7.9%on this news
Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results
Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial HAYWARD, Calif., September 20, 2021 Benitec Biopharma Inc. (NASDAQ: BNTC) ( Benitec or the Company ), a development-stage, gene therapy-focused, biotechnology company developing novel
Read more →BNTCBenitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock
Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock HAYWARD, Calif., April 27, 2021 Benitec Biopharma Inc. (NASDAQ: BNTC) ( Benitec or the Company ), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines ba
Read more →BNTCInterim Results of IND-Enabling Large Animal Study for BB-301 February 2021 Copyright Benitec Biopharma Inc Copyright Benitec Biopharma Ltd 1 www.benitec.com Safe Harbor Statement This presentation contains forward-looki
BB-301 February 2021 Copyright Benitec Biopharma Inc Copyright Benitec Biopharma Ltd 1 www.benitec.comExhibit 99.1 Interim Results of IND-Enabling Large Animal Study for BB-301 February 2021 Copyright Benitec Biopharma Inc Copyright Benitec Biopharma Ltd 1 www.benitec.com Safe
Read more →BNTCBenitec Biopharma Announces Pricing of $10.0 Million Public Offering
Benitec Biopharma Announces Pricing of $10.0 Million Public Offering HAYWARD, Calif., October 2, 2020 Benitec Biopharma Inc. (NASDAQ: BNTC) ( Benitec or the Company ), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on t
Read more →BNTCBenitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results
Benitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results HAYWARD, Calif., September 23, 2020 Benitec Biopharma Inc. (NASDAQ: BNTC) ( Benitec or the Company ), a development-stage, gene therapy-focused, biotechnology company developin
Read more →BNTCBenitec Biopharma Limited (Nasdaq: BNTC) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Benitec Biopharma Ltd. (ASX:BLT) (Nasdaq:BNTC), an Australian biotechnology company engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases, will visit the Nasdaq MarketSite in
Read more →BNTCBenitec Announces Acquisition of Tacere Therapeutics and Phase I/II Ready Hepatitis C (HCV) Program
SYDNEY, AUSTRALIA and SAN JOSE, CA--(Marketwire - Oct 11, 2012) - Benitec Biopharma (ASX: BLT) Acquisition of US-based Tacere Therapeutics brings Phase I/II ready clinical development program in Hepatitis C (HCV) Highly compatible technology based on Benitec Biopharma's novel d
Read more →Competitive Position
How BNTC ranks across every disease it competes inCompetitive Position is a premium feature
See how BNTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial